Singapore markets closed
  • Straits Times Index

    3,204.82
    +2.01 (+0.06%)
     
  • Nikkei

    32,402.41
    -168.62 (-0.52%)
     
  • Hang Seng

    18,057.45
    +402.04 (+2.28%)
     
  • FTSE 100

    7,718.78
    +40.16 (+0.52%)
     
  • Bitcoin USD

    26,638.70
    -94.22 (-0.35%)
     
  • CMC Crypto 200

    568.20
    -8.06 (-1.40%)
     
  • S&P 500

    4,330.00
    -72.20 (-1.64%)
     
  • Dow

    34,070.42
    -370.46 (-1.08%)
     
  • Nasdaq

    13,223.99
    -245.14 (-1.82%)
     
  • Gold

    1,946.40
    +6.80 (+0.35%)
     
  • Crude Oil

    90.53
    +0.90 (+1.00%)
     
  • 10-Yr Bond

    4.4800
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,450.23
    +2.02 (+0.14%)
     
  • Jakarta Composite Index

    7,016.84
    +25.38 (+0.36%)
     
  • PSE Index

    6,142.79
    +48.08 (+0.79%)
     

Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

A struggling economy and a bear market haven't been able to stop Vertex Pharmaceuticals (NASDAQ: VRTX). Vertex's forward multiple comes in at more than four times the upper bounds of this range. Also, the company's forward price-to earnings (P/E) multiple is higher than that of the biotech industry, which is currently about 15.